Skip to content
My WebMD Sign In, Sign Up

Menopause Health Center

Font Size
A
A
A

New Treatment for Menopause Symptoms

2-Drug Combo May Reduce Menopause Symptoms While Building Bone
By
WebMD Health News
Reviewed by Louise Chang, MD

New Menopausal Therapy

June 4, 2007 -- Women seeking to quell the symptoms of menopause and build stronger bones may soon have a new treatment option -- possibly with fewer risks normally associated with traditional hormone replacement therapy (HRT).

In two two-year studies of nearly 4,000 women researchers from Wyeth Pharmaceuticals reported on a new class of drugs known as tissue selective estrogen complex (TSEC) -- medications said to offer the benefits of traditional estrogen while minimizing troubling side effects and risks of traditional HRT. The studies were presented this week at the annual meeting of the Endocrine Society in Toronto.

"We're seeing a number of what I think are going to be significant improvements over the previous generation of HRT. This is really a new generation of treatment," says study researcher James H. Pickar, assistant vice president of clinical research and development at Wyeth Research.

In the research, the TSEC drug, yet to be named, combined a conjugated estrogen (Premarin) with basedoxifene, a drug commonly known as a SERM (selective estrogen receptor modulator). SERMS have some of the benefits of estrogen -- such as helping to increase bone density -- without increasing the risk of breast or endometrial cancer.

But rather than just seeing the benefits of combining two separate medications, Pickar says the surprising effect was greater than the sum of its parts.

"What you get is not simply the addition of one to the other, but a brand new profile. That's what makes it so exciting," says Pickar.

That new profile, he says, appears to offer women all the benefits of HRT -- including better bone density -- while minimizing the risks normally associated with hormone therapy.

NYU professor Steven Goldstein, MD, says if the claims are true, then women might indeed have reason to celebrate. But he cautions that questions on long-term use -- particularly effects on breast tissue -- still hang in the balance.

"If we truly can combine the benefits of estrogen -- relief of hot flashes and vaginal dryness -- with the benefits of a SERM -- including decreased bone fracture with breast and uterine protection -- and not increase the risks previously associated with both treatments ... then this will indeed be a revolution in menopausal medicine," says Goldstein.

But he cautions that questions on long-term use - including any impact on breast tissue -- can only be answered with further research.

What We Know Right Now

In the first of the two new trials being presented, researchers looked at the impact of TSEC on the endometrium (the lining of the uterus) in nearly 4,000 women aged 40 to 75 over the course of two years.

The study showed that new cases of endometrial hyperplasia (a thickening of the lining frequently associated with estrogen therapy and sometimes a precursor to cancer) were similar to placebo. Moreover, there was also no increase in bleeding and spotting or breast pain, all common side effects of hormonal therapy.

In the second study, doctors tested the same TSEC on bone mineral density (BMD). They found that it yielded a greater increase in bone mineral density of the spine and hip when compared with placebo or Evista, another SERM.

Today on WebMD

Menopause Overview Slideshow
Slideshow
Screening Tests for Women
Slideshow
 
thumbnail_man_feeding_woman_strawberry
Slideshow
Overweight man sitting on park bench
Video
 
Managing Menopause
Video
Thyroid exam
Quiz
 
Alcohol Disrupting Your Sleep
Article
senior couple
Article
 
Porous bone
Slideshow
woman collapsed over laundry
Quiz
 
Superfood for Bones
Slideshow
Oh Do You Know the Muffin Top
Article
 

WebMD Special Sections